Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.01 (0.45%)
Bid:
2.01
Ask:
2.19
Spread: 0.18 (8.955%)
Market Cap: £44.34m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Successful Sparkle Power Programme Testing

17 Sep 2025 07:00

RNS Number : 5968Z
Quadrise PLC
17 September 2025
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

17 September 2025

 

Quadrise plc

("Quadrise", "QED" or the "Company")

 

Successful completion of Sparkle Power testing programme

 

Quadrise plc (AIM: QED), the technology company focused on the decarbonisation of shipping and heavy industry through deployment of low emission fuels and biofuels, is pleased to announce the successful completion of proof-of-concept and emissions testing programmes for its MSAR® and bioMSAR™ fuels at the Sparkle Power SA ("Sparkle") plant in El Giral, Panama.

 

These trials mark the first successful application of MSAR® and bioMSAR™ on Everllence (formerly MAN Energy Solutions) 4-stroke engines, expanding the commercial potential of these fuels across additional engine types in energy-intensive sectors seeking cost-effective decarbonisation solutions.

 

Testing on MSAR® and bioMSAR™ fuels was conducted over a 24 hour period on an Everllence 18V32/40 8MW engine. A subsequent shorter run was completed on a Everllence 9L28/32 4MW engine. The trials were conducted by experts from Quadrise and Sparkle, and supported by independent specialists in external engine performance, emissions and fuel testing.

 

The key success criteria of the main trial were met as follows:

 

· Engine efficiency was improved, consistent with results on Wärtsilä diesel engines.

· NOx emissions were reduced by 25% with bioMSAR and 32% with MSAR®.

· Particulate matter emissions were reduced by 20% using both fuels.

 

The Sparkle trials validated the expected performance of MSAR® and bioMSAR™ for commercial deployment and confirmed the fuel injection system modifications required to achieve maximum load. The parties are now jointly planning the next steps towards confirming commercial supply arrangements for Sparkle and fuel permitting in Panama.

Jason Miles, Chief Technology Officer of Quadrise, commented:

"The successful trials with Sparkle represent a significant milestone for Quadrise, demonstrating the viability of MSAR® and bioMSAR™ on Everllence 4-stroke engines through a strong collaborative endeavour. With confirmed improvements in engine efficiency and emissions, we look forward to advancing discussions with Sparkle and a regional supply partner to establish a commercial supply facility serving the power and marine sectors across Central America."

Jose Castillo, General Manager of Sparkle, commented:

 

"We are delighted to have completed the Everllence engine test of MSAR® and bioMSAR™ at our power plant. The Quadrise test has confirmed the fuels are viable replacements for heavy fuel oil at our facility.

Sparkle Power is committed to becoming more fuel efficient and conserving the environment by reducing emissions in accordance with the government's policies for environmental conservation in Panama. The test has confirmed that MSAR® and bioMSAR™ fuels can achieve the necessary criteria for commercial implementation in the country."

 

For further information please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Technology Officer

 

 

Nominated Adviser

Cavendish Capital Markets Limited

 

 

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

 

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs, Harry Davies-Ball (Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

 

 

+44 (0)20 3005 5000

 

Public & Investor Relations

 

 

Tavistock Communications (Financial PR & IR)

Simon Hudson

Nick Elwes

Ruairi Millar

 

+44 (0) 20 7920 3150

 

 BLUE Communications Limited (Marine & Trade PR)

 Rhys Thomas

 Sam Deacon

 

 

 

+44 (0)7595 227750

+44 (0)7527 558846

 

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to lower energy costs, pollution and greenhouse gas emissions today for the global power generation, shipping, industrial and oil industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X: @QuadrisePlc

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFFTASIRLIE
Date   Source Headline
9th Jun 20144:30 pmRNSDirector/PDMR Shareholding
3rd Jun 20144:30 pmRNSDirector/PDMR Shareholding
3rd Jun 20144:30 pmRNSTotal Voting Rights
2nd Jun 20144:31 pmRNSBlocklisting Interim Review
2nd Jun 20144:30 pmRNSHolding(s) in Company
28th May 20144:30 pmRNSHolding(s) in Company
28th May 20144:29 pmRNSAdditional Listing
27th May 20144:30 pmRNSDirector/PDMR Shareholding
23rd May 20147:00 amRNSFinal Results for the year ended 31 March 2014
16th May 20147:00 amRNSDisposal of share in iQ JV to Wellcome Trust
8th May 20149:01 amRNSNotice of Results
7th May 20144:30 pmRNSDirector/PDMR Shareholding
2nd May 20144:01 pmRNSTotal Voting Rights
2nd May 20144:00 pmRNSDirector/PDMR Shareholding
1st May 20147:00 amRNSQuintain acquires Aldermary House, EC4
14th Apr 20147:00 amRNSRe Joint Venture at Wembley Park
11th Apr 20144:38 pmRNSHolding(s) in Company
9th Apr 20144:31 pmRNSReplacement Director/PDMR Shareholding
2nd Apr 20144:31 pmRNSTotal Voting Rights
2nd Apr 20144:30 pmRNSDirector/PDMR Shareholding
26th Mar 20144:30 pmRNSHolding(s) in Company
26th Mar 20143:00 pmRNSDirector Declaration
11th Mar 20149:03 amRNSDirector/PDMR Shareholding
4th Mar 20144:31 pmRNSTotal Voting Rights
4th Mar 20144:30 pmRNSDirector/PDMR Shareholding
14th Feb 20145:17 pmRNSHolding(s) in Company
12th Feb 20144:30 pmRNSHolding(s) in Company
12th Feb 20147:00 amRNSDisposal of interest in Mitre Passage
12th Feb 20147:00 amRNSInterim Management Statement
7th Feb 20147:00 amRNSQuintain acquires Kingsbourne House
4th Feb 20144:31 pmRNSTotal Voting Rights
4th Feb 20144:28 pmRNSDirector/PDMR Shareholding
30th Jan 20144:30 pmRNSDirector/PDMR Shareholding
7th Jan 20144:32 pmRNSBlocklisting Interim Review
7th Jan 20144:31 pmRNSBlocklisting Interim Review
7th Jan 20144:30 pmRNSDirector/PDMR Shareholding
7th Jan 20144:30 pmRNSDirector/PDMR Shareholding
7th Jan 20144:30 pmRNSTotal Voting Rights
27th Dec 20139:43 amRNSHolding(s) in Company
10th Dec 20139:30 amRNSDirector/PDMR Shareholding
5th Dec 20131:05 pmRNSHolding(s) in Company
3rd Dec 20139:30 amRNSHolding(s) in Company
3rd Dec 20139:06 amRNSTotal Voting Rights
3rd Dec 20139:05 amRNSDirector/PDMR Shareholding
25th Nov 20137:00 amRNSResults for the six months ended 30 September 2013
21st Nov 20131:15 pmRNSGeneral Meeting voting results
8th Nov 20134:00 pmRNSNotice of Interim Results
7th Nov 20134:30 pmRNSDirector/PDMR Shareholding
7th Nov 201311:00 amRNSHolding(s) in Company
6th Nov 20139:00 amRNSChange in Director's details

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.